Respiratory disease and early serum S100A12 changes in very premature infants
Article first published online: 11 JUL 2011
© 2011 The Author(s)/Acta Pædiatrica © 2011 Foundation Acta Pædiatrica
Volume 100, Issue 12, pages 1538–1543, December 2011
How to Cite
Loughran-Fowlds, A., Leach, S., Lin, J., Oei, J., Henry, R., Day, A. S. and Lui, K. (2011), Respiratory disease and early serum S100A12 changes in very premature infants. Acta Paediatrica, 100: 1538–1543. doi: 10.1111/j.1651-2227.2011.02384.x
- Issue published online: 8 NOV 2011
- Article first published online: 11 JUL 2011
- Accepted manuscript online: 14 JUN 2011 11:01AM EST
- Received 12 December 2010; revised 23 March 2011; accepted 9 June 2011.
- Bronchopulmonary dysplasia;
- Neonatal respiratory distress syndrome;
- Premature infants;
- S-100 protein
Aim: The role of granulocyte-specific S100A12, a marker for inflammatory disorders, in newborn lung disease is unknown. We compared postnatal blood S100A12 concentrations against respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD).
Methods: Blood samples from 92 newborns were collected on admission, 12 h, day 1, day 3–4 and day 7, and analysed for S100A12. IL-8 and IL-6 were assayed in 52 infants.
Results: Infants with RDS were significantly more premature (median 27 vs. 34 weeks), more likely to receive antenatal corticosteroids (84% vs. 26%) and have lower neutrophil counts (median 2.4 vs. 3.8 × 109/L) at admission. S100A12 levels peaked during the first day and were significantly lower in preterm infants with RDS compared to those without (median 250 vs. 616 ng/mL at 12 h, 281 vs. 828 ng/mL day 1, respectively). S100A12 levels were low among the 35 very preterm infants (24–29 week gestation) regardless of the presence of BPD (285 vs. 288 ng/mL on day 1). In comparison, IL-8 and IL-6 levels were not different between groups.
Conclusion: Plasma S100A12 is low in infants with RDS, possibly because of gestationally related differences in neutrophil response or to the effects of antenatal corticosteroids. It is therefore not a useful marker of BPD development.